Please use this identifier to cite or link to this item:
|Scopus||Web of Science®||Altmetric|
|Title:||New drugs for HDL-C disorders: the beginning|
|Citation:||Current Medicinal Chemistry, 2014; 21(25):2947-2951|
|Publisher:||Bentham Science Publishers|
|MyNgan Duong and Stephen J. Nicholls|
|Abstract:||For more than 20 years there has been increasing interest in the development of novel therapies to raise levels of high-density lipoprotein cholesterol (HDL-C). However, well publicized failures of recent clinical trials of agents that raise HDL-C levels have stimulated considerable controversy with regard to the potential clinical utility of this therapeutic target. A number of classes of agents are currently under investigation with variable effects on HDL quantity and quality. These will be reviewed.|
|Keywords:||Atherosclerosis; cardiovascular disease; HDL; lipids; risk factors|
|Rights:||© 2016 Bentham Science Publishers|
|Appears in Collections:||Aurora harvest 3|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.